Search Results for 'survival pfs'

survival pfs published presentations and documents on DocSlides.

Blinded Sample Size Re-estimation in a Phase III Study Investigating Progression Free Survival

Blinded Sample Size Re-estimation in a Phase III Study Investigating Progression Free Survival

by naomi

David Morgan (King’s College, London / Consultan...

End-points utilized in breast cancer

End-points utilized in breast cancer

by evelyn

clinical . trials - Discussion. Novartis Oncology...

End-points utilized in

End-points utilized in

by marina-yarberry

End-points utilized in breast cancer clinical ...

Blinded Sample Size Re-estimation in a Phase III Study Inve

Blinded Sample Size Re-estimation in a Phase III Study Inve

by luanne-stotts

David Morgan (King’s College, London / Consulta...

Managing Advanced Renal Cell

Managing Advanced Renal Cell

by debby-jeon

Carcinoma: Balancing . Efficacy with Quality of L...

Jointly provided by & This activity is supported by educations grants from Novartis Pharmaceuticals Corporation, Pfizer, and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com

Jointly provided by & This activity is supported by educations grants from Novartis Pharmaceuticals Corporation, Pfizer, and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com

by olivia-moreira

Jointly provided by ...

ESMO 2021 (Virtual) Congress Report

ESMO 2021 (Virtual) Congress Report

by SnuggleBug

Lung and gastrointestinal cancers. Slide numbers. ...

YIR On Demand Lung Benjamin Levy, MD

YIR On Demand Lung Benjamin Levy, MD

by jovita

Assistant Professor. Johns Hopkins School of Medic...

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Ref

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Ref

by willow

Meletios Dimopoulos,. 1. Hang Quach,. 2. Maria-V...

End-Points and Rationale for Phase III Trials in HCC: Adjuvant, Intermediate, and Advanced HCC

End-Points and Rationale for Phase III Trials in HCC: Adjuvant, Intermediate, and Advanced HCC

by maniakti

Richard S. Finn, MD. Professor of Clinical Medicin...

Analysis of Sustained MRD-Negativity and Progression-Free Survival of Isa-KRd in High-Risk Newly Diagnosed Multiple Myeloma Additional Data From Planned Interim Analysis of the GMMG-CONCEPT Trial

Analysis of Sustained MRD-Negativity and Progression-Free Survival of Isa-KRd in High-Risk Newly Diagnosed Multiple Myeloma Additional Data From Planned Interim Analysis of the GMMG-CONCEPT Trial

by ayaan

Progression-Free Survival of Isa-. KRd. in High-R...

Indolent Non-Hodgkin L

Indolent Non-Hodgkin L

by danika-pritchard

ymphoma. Sobia Ozair. March 8, 2017. MD Anderson ...

Update on transplant-ineligible patients:

Update on transplant-ineligible patients:

by trish-goza

Which . regimens are best?. Suzanne Lentzsch MD, ...

INTRODUCTION RESULTS

INTRODUCTION RESULTS

by arjun383

Mason Alford, MSc. a. , . Candace J. Grisham, MS. ...

Meeting summary ASCO GU 2020,

Meeting summary ASCO GU 2020,

by patricia

San Francisco. , USA. Assoc. . Prof. . Shilpa Gupt...

GI CONNECT MEETING SUMMARY

GI CONNECT MEETING SUMMARY

by hanah

upper . gi. cancer HIGHLIGHTS . FROM ESMO 2022. D...

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor

by byrne

Overall survival and updated progression-free surv...

First Prospective Data on Minimal Residual Disease (MRD) Outcomes After Fixed-Duration Ibrutinib P

First Prospective Data on Minimal Residual Disease (MRD) Outcomes After Fixed-Duration Ibrutinib P

by mia

Ibr+Ven. ) Versus Chlorambucil Plus Obinutuzumab (...

The Impending D eath of Cancer:

The Impending D eath of Cancer:

by elina

A Herculean Task. Emerging Therapies 2016. Ruemu E...

Updates on T-cell lymphoma

Updates on T-cell lymphoma

by grace3

Dr. Stefan K. Barta. University of Pennsylvania, U...

Advances in Systemic Amyloidosis:

Advances in Systemic Amyloidosis:

by morton

A Spotlight on New Disease-Modifying . Therapies A...

Molecular Lessons Learnt from Clinical Trials in the Last Decade

Molecular Lessons Learnt from Clinical Trials in the Last Decade

by altigan

Andrew X. Zhu, MD, PhD. Harvard Medical School. Ma...

by billiontins

2018;36(8):773-9.. Nivolumab Monotherapy (Cohort 1...

Romidepsin in Association with CHOP in Patients with Peripheral T

Romidepsin in Association with CHOP in Patients with Peripheral T

by accompanypepsi

-Cell . Lymphoma: Final Results of the Phase . Ib....

NEw developments IN gynecological Oncology

NEw developments IN gynecological Oncology

by cheryl-pisano

highlights from the. EUROPEAN . society . of med...

Overall Survival Benefit of

Overall Survival Benefit of

by tatyana-admore

Obinutuzumab. Over Rituximab when Combined with ...

The Impending D eath of Cancer: A Herculean Task Emerging Therapies 2016

The Impending D eath of Cancer: A Herculean Task Emerging Therapies 2016

by phoebe-click

The Impending D eath of Cancer: A Herculean Task...

Emanuele Zucca, MD Oncology Institute of Southern Switzerland (IOSI)

Emanuele Zucca, MD Oncology Institute of Southern Switzerland (IOSI)

by ellena-manuel

Swiss Group for Clinical Cancer Research (SAKK). ...

Jon Trent, MD, PhD Professor of Medicine

Jon Trent, MD, PhD Professor of Medicine

by jane-oiler

Sarcoma . Medical Oncology. The University of . M...

by alida-meadow

treatments. in WT . pts. : . which. . opportuni...

Department of GI Medical Oncology

Department of GI Medical Oncology

by danika-pritchard

Does . the New EPOC trial . eliminate. . Anti. -...

Have the OPTIMOX-2, CAIRO-3, COIN, DREAM and other recent t

Have the OPTIMOX-2, CAIRO-3, COIN, DREAM and other recent t

by sherrill-nordquist

Yes . Deborah . Schrag. , MD, MPH. No. John L. Ma...